Chromosomal instability and inflammation: a catch-22 for cancer cells.


Journal

Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology
ISSN: 1573-6849
Titre abrégé: Chromosome Res
Pays: Netherlands
ID NLM: 9313452

Informations de publication

Date de publication:
10 08 2023
Historique:
received: 01 06 2023
accepted: 27 07 2023
revised: 13 07 2023
medline: 11 8 2023
pubmed: 10 8 2023
entrez: 10 8 2023
Statut: epublish

Résumé

Chromosomal instability (CIN), an increased rate of chromosomal segregation abnormalities, drives intratumor heterogeneity and affects most human cancers. In addition to chromosome copy number alterations, CIN results in chromosome(s) (fragments) being mislocalized into the cytoplasm in the form of micronuclei. Micronuclei can be detected by cGAS, a double-strand nucleic acid sensor, which will lead to the production of the second messenger 2'3'-cGAMP, activation of an inflammatory response, and downstream immune cell activation. However, the molecular network underlying the CIN-induced inflammatory response is still poorly understood. Furthermore, there is emerging evidence that cancers that display CIN circumvent this CIN-induced inflammatory response, and thus immune surveillance. The STAT1, STAT3, and NF-κB signaling cascades appear to play an important role in the CIN-induced inflammatory response. In this review, we discuss how these pathways are involved in signaling CIN in cells and how they are intertwined. A better understanding of how CIN is being signaled in cells and how cancer cells circumvent this is of the utmost importance for better and more selective cancer treatment.

Identifiants

pubmed: 37561163
doi: 10.1007/s10577-023-09730-y
pii: 10.1007/s10577-023-09730-y
pmc: PMC10415485
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19

Informations de copyright

© 2023. The Author(s).

Références

Clin Cancer Res. 2019 Jul 1;25(13):3996-4013
pubmed: 30867218
Cells. 2019 Oct 10;8(10):
pubmed: 31658669
Open Biol. 2020 Sep;10(9):200148
pubmed: 32873156
Int J Mol Sci. 2021 Jan 09;22(2):
pubmed: 33435349
Nature. 2023 Jul;619(7968):184-192
pubmed: 37286600
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Cell Rep. 2022 Dec 6;41(10):111774
pubmed: 36476853
Nature. 2022 Jul;607(7920):776-783
pubmed: 35859176
Mol Cancer. 2013 Aug 02;12:86
pubmed: 23915189
Nature. 2022 Jul;607(7920):784-789
pubmed: 35859175
Cell Rep. 2022 Nov 1;41(5):111568
pubmed: 36323249
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
pubmed: 9636188
Cell Res. 2008 Apr;18(4):443-51
pubmed: 18364677
Nat Rev Mol Cell Biol. 2015 Aug;16(8):473-85
pubmed: 26204159
Apoptosis. 2022 Dec;27(11-12):961-978
pubmed: 36018392
Cancer Discov. 2021 May;11(5):1212-1227
pubmed: 33372007
Nature. 2015 Apr 23;520(7548):553-7
pubmed: 25642965
Cold Spring Harb Perspect Med. 2017 Jun 1;7(6):
pubmed: 28213433
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
Oncogene. 2011 Apr 7;30(14):1615-30
pubmed: 21170083
Int J Cancer. 2015 May 15;136(10):2341-51
pubmed: 25359525
NPJ Precis Oncol. 2023 Jun 3;7(1):54
pubmed: 37270587
Life (Basel). 2020 Nov 08;10(11):
pubmed: 33171596
Sci Rep. 2021 Mar 31;11(1):7243
pubmed: 33790360
Bioessays. 2018 Jan;40(1):
pubmed: 29160563
Oncoimmunology. 2019 Sep 6;8(11):1657374
pubmed: 31646083
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
J Clin Invest. 2012 Apr;122(4):1138-43
pubmed: 22466654
Cell. 2018 Sep 6;174(6):1347-1360
pubmed: 30193109
Gut. 2008 Jul;57(7):941-50
pubmed: 18364437
Trends Cancer. 2023 Jan;9(1):83-92
pubmed: 36216730
Oncogene. 2018 Apr;37(15):2037-2051
pubmed: 29367762
Nat Cell Biol. 2019 Jan;21(1):54-62
pubmed: 30602769
Dev Cell. 2020 Feb 24;52(4):413-428.e6
pubmed: 32097652
Nature. 2022 Jul;607(7920):769-775
pubmed: 35859177
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
J Hematol Oncol. 2020 Jun 22;13(1):81
pubmed: 32571374
Sci Adv. 2021 Dec 17;7(51):eabf9441
pubmed: 34910513
Nature. 2022 Jul;607(7918):366-373
pubmed: 35705809
Oncoimmunology. 2015 Mar 2;4(6):e1008824
pubmed: 26155422
Nature. 2018 Jan 25;553(7689):467-472
pubmed: 29342134
Nature. 2017 Aug 24;548(7668):461-465
pubmed: 28738408
Proc Natl Acad Sci U S A. 2021 Nov 30;118(48):
pubmed: 34819364
Trends Genet. 2011 Nov;27(11):446-53
pubmed: 21872963
Br J Cancer. 2022 Sep;127(4):603-611
pubmed: 35383278
Bioessays. 2001 Feb;23(2):161-9
pubmed: 11169589
Nature. 2023 Jan;613(7942):187-194
pubmed: 36544021
Cytokine. 2017 Jan;89:12-20
pubmed: 26631912
Oncol Rep. 2013 Jun;29(6):2303-10
pubmed: 23588992
Nature. 2023 Jul;619(7968):176-183
pubmed: 37286593
Nature. 2021 Mar;591(7850):477-481
pubmed: 33627873
Immunol Lett. 2010 Jan 4;127(2):100-7
pubmed: 19900478
BMC Cancer. 2013 May 22;13:252
pubmed: 23694679
Immunol Cell Biol. 2013 Oct;91(9):556-67
pubmed: 23958683
Dev Cell. 2017 Jun 19;41(6):638-651.e5
pubmed: 28633018
Oncoimmunology. 2020 Jun 16;9(1):1777624
pubmed: 32934881
Biochem Soc Trans. 2023 Apr 26;51(2):539-555
pubmed: 36876871
Nat Genet. 2022 Dec;54(12):1782-1785
pubmed: 36443443
Genes Dev. 2011 Oct 1;25(19):2041-56
pubmed: 21979917
Cancer Res. 2011 Mar 1;71(5):1858-70
pubmed: 21363922
Br J Cancer. 2013 Jul 9;109(1):138-46
pubmed: 23756862
PLoS One. 2021 Apr 28;16(4):e0240145
pubmed: 33909625
Int J Cancer. 2019 Nov 1;145(9):2568-2579
pubmed: 30924133
Cell. 2019 Jul 11;178(2):302-315.e23
pubmed: 31299200
Dev Cell. 2018 Feb 26;44(4):420-431
pubmed: 29486194
EMBO Rep. 2021 Aug 4;22(8):e52032
pubmed: 34105235
Dev Cell. 2021 Sep 13;56(17):2440-2454.e6
pubmed: 34352223
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
JAKSTAT. 2012 Apr 1;1(2):65-72
pubmed: 24058752
Blood. 2007 Jul 1;110(1):296-304
pubmed: 17363736
Genes Chromosomes Cancer. 2020 Nov;59(11):627-638
pubmed: 32557940
Nat Commun. 2023 Feb 2;14(1):556
pubmed: 36732527
BMC Cancer. 2014 Feb 22;14:121
pubmed: 24559140
Annu Rev Cell Dev Biol. 2012;28:189-214
pubmed: 22804579
Nat Immunol. 2020 Jan;21(1):17-29
pubmed: 31819255
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Nature. 2022 Jun;606(7914):594-602
pubmed: 35614224

Auteurs

Anouk van den Brink (A)

European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Antonius Deusinglaan 1, 9713, AV, Groningen, The Netherlands.

Maria F Suárez Peredo Rodríguez (MF)

European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Antonius Deusinglaan 1, 9713, AV, Groningen, The Netherlands. m.f.suarez.peredo.rodriguez@umcg.nl.

Floris Foijer (F)

European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Antonius Deusinglaan 1, 9713, AV, Groningen, The Netherlands. f.foijer@umcg.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH